Supplementary Materials
The PDF file includes:
- Materials and Methods
- Fig. S1. REGN4018 lacks antibody-dependent cell-mediated cytotoxicity and complement dependent cytotoxicity functions.
- Fig. S2. PD-1 and CD25 are up-regulated in response to both REGN4018 and anti-CD3/anti-CD28 stimulation.
- Fig. S3. REGN4018 binds CA-125 to a much lower degree than anti-MUC16 clone 3A5.
- Fig. S4. REGN4018 did not induce any weight loss in animals with detectable drug concentrations.
- Fig. S5. MUC16 expression is maintained in vivo after REGN4018 treatment.
- Fig. S6. BLI at baseline correlates with complete tumor clearance.
- Fig. S7. Human T cells are maintained after transfer of human PBMCs and can respond to anti-CD3 or REGN4018.
- Fig. S8. Antitumor efficacy and cytokine induction by REGN4018 require T cells and MUC16-expressing OVCAR-3/Luc cells.
- Fig. S9. PD-1 blockade enhances efficacy of suboptimal REGN4018 in the xenogenic OVCAR-3 model.
- Fig. S10. MUC16 expression in the lung from cynomolgus monkey.
- References (42–46)
Other Supplementary Material for this manuscript includes the following:
- Data file S1 (Microsoft Excel format). Primary data.
